Veru Announces Proposed Public Offering of Common Stock
13 Dezembro 2023 - 6:01PM
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical
company focused on developing novel medicines for the treatment of
metabolic diseases, oncology and viral-induced acute respiratory
distress syndrome, announced today that it has commenced an
underwritten public offering of shares of its common stock. All
shares of common stock to be sold in the offering will be offered
by Veru. In addition, Veru intends to grant the underwriters a
30-day option to purchase up to an additional 15% of the shares of
its common stock offered in the public offering at the public
offering price, less underwriting discounts and commissions. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Raymond James & Associates, Inc. and Oppenheimer & Co.
Inc. are acting as joint book-running managers for the
offering.
Veru intends to use the net proceeds from the proposed offering
to fund its clinical stage drug development with a primary
near-term focus on funding a Phase 2b clinical trial designed to
evaluate the safety and efficacy of enobosarm, an oral selective
androgen receptor modulator, initially as a treatment to augment
fat loss and to prevent muscle loss in sarcopenic obese or
overweight elderly patients receiving a glucagon-like peptide-1
receptor agonist who are at-risk for developing muscle atrophy and
muscle weakness. Some of the proceeds will also be used for working
capital purposes, including existing vendor obligations and for
other general corporate purposes.
The securities described above are being offered by Veru
pursuant to a shelf registration statement on Form S-3 previously
filed with the Securities and Exchange Commission (SEC) on March
16, 2023 which was amended on April 11, 2023 and declared effective
by the SEC on April 14, 2023. This offering is being made only by
means of a prospectus and prospectus supplement that form a part of
the registration statement. A preliminary prospectus supplement
related to the offering will be filed with the SEC and will be
available on the website of the SEC at http://www.sec.gov. Copies
of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may also be obtained when
available by contacting Raymond James & Associates, Inc.,
Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg,
Florida 33716, or by telephone at (800) 248-8863, or by e-mail to
prospectus@raymondjames.com; or Oppenheimer & Co. Inc.,
Attention: Syndicate Prospectus Department, 85 Broad Street, 26th
Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by
email at EquityProspectus@opco.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
state or jurisdiction.
About Veru Inc.Veru Inc. is a late clinical
stage biopharmaceutical company focused on developing novel
medicines for the treatment of metabolic diseases, oncology and
viral-induced acute respiratory distress syndrome.
Cautionary Statement on Forward Looking
StatementsThis press release contains "forward-looking
statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995 , including, without limitation,
express or implied statements related to Veru’s expectations
regarding the timing of the proposed public offering, the size and
expected gross proceeds from the offering, the anticipated use of
proceeds from the proposed offering and the grant to the
underwriters of an option to purchase additional shares. as The
words "anticipate," "believe," "could," "expect, " "intend," "may,"
"opportunity," "plan," "predict," "potential," "estimate," "should,
" "will," "would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements in this press release are based upon current plans and
strategies of Veru Inc. (the Company) and reflect the Company's
current assessment of the risks and uncertainties related to its
business and are made as of the date of this press release. The
Company assumes no obligation to update any forward- looking
statements contained in this press release because of new
information or future events, developments or circumstances. Such
forward-looking statements are subject to known and unknown risks,
uncertainties and assumptions, and if any such risks or
uncertainties materialize or if any of the assumptions prove
incorrect, our actual results could differ materially from those
expressed or implied by such statements. Factors that may cause
actual results to differ materially from those contemplated by such
forward-looking statements include, but are not limited to,
uncertainties related to market conditions and the satisfaction of
customary closing conditions related to the proposed public
offering and the Company’s expectations regarding the completion,
timing and size of the proposed public offering and the use of
proceeds therefrom. This list is not exhaustive and other risks are
detailed in the Company’s periodic reports filed with the SEC,
including the Company's Form 10-K for the year ended September 30,
2023.
Contact:
Sam Fischveruinvestor@verupharma.comExecutive Director, Investor
Relations and Corporate Communications
Veru (NASDAQ:VERU)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Veru (NASDAQ:VERU)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024